Novartis multiple myeloma drug Farydak OK'd; black box imposed

The FDA has given Novartis the green light to market Farydak (panobinostat), a potent pan-deacetylase inhibitor, as a treatment for multiple myeloma, a disease that affects about 21,700 Americans each year, killing 10,710.